CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

blood samplesWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1446 McGrath videolaryngoscope Wiki 0.71
drug777 Direct laryngoscope Wiki 0.71
drug1860 Placebos Wiki 0.17
drug1086 Hydroxychloroquine Wiki 0.07

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D009410 Nerve Degeneration NIH 0.71
D004660 Encephalitis NIH 0.71
D007040 Hypoventilation NIH 0.50
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0002383 Encephalitis HPO 0.71
HP:0002180 Neurodegeneration HPO 0.71
HP:0002791 Hypoventilation HPO 0.50

There are 2 clinical trials

Clinical Trials

1 Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France)

On 17th March 2020, 198 193 confirmed cases (7 730 in France) of COVID-19 infections and 7 854 deaths (175 in France) have been reported from 8th December 2019 in 157 countries. The rapid increase in cases on french territory has led to the transition of France to level 3 of the epidemic on 14th March 2020. The natural history of the disease is still poorly understood, especially prognostic factors, which are crucial for the best medical care of patients in times of epidemics, when hospital capacities are under pressure. A better knowledge of natural history, of prognostic factors, the development and validation of new diagnostic tests, the evaluation of medical care, will lead to a better medical care of patients infected with COVID-19.

NCT04352348 COVID-19 Other: blood samples

Primary Outcomes

Description: Research of prognostic factors which could be implicated in the progression to severe form of COVID-19 infection.

Measure: Identification of prognostic factors for progression to a severe form of COVID-19 infection

Time: 12 months

Secondary Outcomes

Measure: Clinical aggravation of the infection

Time: 12 months

Measure: Discharge of hospitalization

Time: 12 months

Measure: Death

Time: 12 months

Measure: Description of clinical manifestations

Time: 12 months

Measure: Description of biological manifestations

Time: 12 months

Measure: Description of radiological manifestations

Time: 12 months

Measure: Description of physiological manifestations

Time: 12 months

Measure: Patient-related prognostic factors

Time: 12 months

Measure: Virus-related risk factors

Time: 12 months

Measure: Comparison of the results of different diagnosis tests

Time: Up to 12 months

2 Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid

Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.

NCT04361344 COVID-19 Infection Encephalitis Biological: blood samples
MeSH:Infection Communicable Diseases Encephalitis Nerve Degeneration
HPO:Encephalitis Neurodegeneration

Primary Outcomes

Description: Change of neurofilament light chain (NFL) (pg/ml) level between first day of hospitalisation and one week; and change of GFAP (pg/ml) level between first day of hospitalisation and one week.

Measure: Change of neurodegeneration markers level

Time: Level of neurofilament light chain (NFL) is dosed at inclusion (day 0) and week 1. Level of GFAP is dosed at inclusion (day 0) and week 1 (day 7).

Related HPO nodes (Using clinical trials)

HP:0002383: Encephalitis
Genes 33
RFXANK IL23R IL12A PRF1 HLA-B XIAP ERAP1 BCL10 LBR BTK HYOU1 CCR1 RFX5 STAT1 KLRC4 TMEM70 RFXAP MEFV SH2D1A BTK L2HGDH C4A IL12A-AS1 SLC6A19 UBAC2 TLR4 IRF3 IL10 ATRX CIITA FAS IKBKG STAT4
Protein Mutations 0
SNP 1
rs6971
HP:0002180: Neurodegeneration
Genes 82
IDUA PANK2 PFN1 COASY OPTN UCHL1 TTC19 PDE8B DAO NARS2 CHMP2B ANG C9ORF72 GLT8D1 VAPB CFAP410 UNC13A DCTN1 TREX1 TBK1 TANGO2 GM2A CSF1R FTL UBTF RNASEH2C PON2 PON1 AARS2 TREM2 GALC ZBTB20 ANXA11 PPARGC1A FA2H PCNA NEFH HNRNPA1 RNASEH2A SOD1 LYST WDR45 C19ORF12 FIG4 ERBB4 UBQLN2 NBN PCNA TAF15 PRPH MAPT MFSD8 SQSTM1 ADAR RNASEH2B EPHA4 ATXN2 ATXN3 VCP IFIH1 PLA2G6 TARDBP FUS ATXN3 GM2A TXN2 SAMHD1 NAXD GLE1 PLA2G6 IDS FOLR1 ABCD1 CHCHD10 MATR3 COQ2 PON3 ATXN3 PRNP GUSB NEK1 CCNF
Protein Mutations 4
G2019S G2385R R1628P V600E
SNP 1
rs6971